Sonoma Pharmaceuticals (NASDAQ: SNOA - Get Free Report) and Indivior (NASDAQ: INDV - Get Free Report

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr.,

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti,

RICHMOND, Va., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) (“In

INDV, IRWD, RLMD, LRMR and CRDL could offer significant upside as biotech sentiment improves, backed

HighTower Advisors LLC acquired a new stake in Indivior PLC (NASDAQ: INDV) during the second quarter

Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Indivior Pharmaceutica

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merge

INDV's proposed Supernus merger could broaden its CNS portfolio, cut costs and reduce reliance on Su

Indivior (NASDAQ:INDV) released second-quarter financial results and hosted an earnings call on Tues

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of [url="]Kahn Swic

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr.,

Barclays analyst Glen Santangelo maintains Indivior Pharmaceuticals (NASDAQ:INDV) with a Overweig

Indivior announces a merger with Supernus to form a CNS-focused biopharma company, tops Q2 earnings

The most oversold health care stocks present a buying opportunity. RSI indicator compares stock stre

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Indivior Pharmaceuticals,

NEW YORK, Aug. 3, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Asso

Supernus Pharmaceuticals (SUPN) has seen its stock rise following the announcement of an all-stock m

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) and Indivior Pharmaceuticals Inc. (NASDAQ:INDV) on Mond

Supernus and Indivior agree to merge in an all-stock deal, targeting $2.2 billion in revenue and $12

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merge

Indivior Pharmaceuticals Inc. (INDV) came out with quarterly earnings of $1.15 per share, beating th

Supernus Pharmaceuticals and Indivior Pharmaceuticals said on Monday they had agreed to an all-stock

Indivior Pharmaceuticals (NASDAQ:INDV) raises FY2026 sales outlook from $1.215 billion-$1.285 billio

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) and Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) today

•   Q2'26 Total Net Revenue of $ 343 Million, Up 14% YoY •   Record Quarterly Total SUBLOCADE® Net R

Barclays analyst Glen Santangelo initiates coverage on Indivior Pharmaceuticals (NASDAQ:INDV) wit

Kevin Mahn highlighted the potential impact of the recent tariff noise on the market and advised inv

https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20251205-1480992/1480992_decembe

Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings

Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnin

Companies Reporting Before The Bell • SES AI (NYSE:SES) is projected to report quarterly earnings a